DePuy Ireland UC

DePuy Ireland UC specialises in orthopaedic surgical instruments and implant systems. Their portfolio includes reusable tools like acetabular orthopaedic reamers, orthopaedic impactors, and bone-cutting forceps, as well as single-use items such as joint prosthesis implantation kits and knee arthroplasty wedges. They also produce advanced systems like a multi-purpose stereotactic surgery system and specific prosthesis components, including hip systems with antibiotic bone cement.

DePuy Ireland UC is based in Ireland, which allows it to operate under EU medical device regulations. Since their devices are classified under EU Class I, II, IIa, and IIb, they must comply with EUDAMED listing requirements and other relevant EU directives. This geographic positioning also means their devices may be subject to additional scrutiny or pathways depending on the market they enter, such as the FDA’s 510(k) process in the U.S.

DePuy Ireland UC’s devices are listed in EUDAMED, the European Union’s medical device registry, and the FDA’s 510(k) database for the U.S. market. Listing in these databases demonstrates compliance with regulatory requirements in those regions, ensuring transparency for healthcare providers, authorities, and patients. It also helps streamline traceability and post-market surveillance efforts.

DePuy Ireland UC’s devices fall into Class I, II, IIa, and IIb under EU medical device regulations. Classification determines the level of scrutiny and regulatory controls required—higher classes (e.g., IIb) involve stricter pre-market assessments, clinical evaluations, and post-market monitoring due to increased risk. For example, joint prosthesis components like the Prostalac Hip System would likely be Class IIb, requiring detailed safety and performance data before authorisation.

Yes, DePuy Ireland UC’s devices are authorised in both the EU (via CE marking) and the U.S. (via FDA clearance). The authorisation process differs by region: in the EU, compliance with MDD/IVDR and classification determines CE marking, while in the U.S., devices must demonstrate substantial equivalence to a predicate through the 510(k) pathway. Listing in EUDAMED and FDA’s 510(k) database reflects this dual-market compliance.